Identification of Early Breast Cancer Patients with Limited Axillary Disease that Can Be Spared from Routine Axillary Nodal Clearance in Upfront Cases

Zenab Noorain; Ayesha Javed; Syeda Rifaat Qamar  Naqvi; Saman Naz Naz; Marrium  Khurshid; Hira  Ijaz

doi:10.51253/pafmj.v76iSUPPL-8.14150

Authors

Zenab Noorain Department of Breast Surgery, Combined Military Hospital, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Ayesha Javed Department of Breast Surgery, Combined Military Hospital, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Syeda Rifaat Qamar Naqvi Department of Breast Surgery, Combined Military Hospital, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Saman Naz Naz Department of Breast Surgery, Combined Military Hospital, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Marrium Khurshid Department of Breast Surgery, Combined Military Hospital, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Hira Ijaz Department of Breast Surgery, Combined Military Hospital, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan https://orcid.org/0009-0009-4293-1317

DOI:

https://doi.org/10.51253/pafmj.v76iSUPPL-8.14150

Keywords:

Axillary, Breast Neoplasm, Biopsy, Lymph Node Dissection, Sentinel

Abstract

Objective: To compare clinically assessed limited axillary disease with final histopathological findings in breast cancer patients treated surgically as upfront cases and to determine the accuracy of clinical axillary assessment and its implications for contemporary axillary management.

Study Design: Diagnostic cross-sectional study.

Place and Duration of Study: Department of Breast Surgery, Combined Military Hospital, Rawalpindi, Pakistan from Feb to Nov 2025.

Methodology: A total of 420 patients were analyzed. Primary variable studied was the accuracy of preoperative clinical axillary assessment in identifying limited axillary disease, using final histopathological nodal status as the gold standard.

Results: The sensitivity of clinical axillary assessment was calculated as 58.0%, specificity was 90.9%, the positive predictive value was 83.8%, while the negative predictive value was 72.8%. The overall diagnostic accuracy of clinical axillary assessment was 76.2%. Agreement between clinically assessed limited axillary disease and final histopathological nodal status was evaluated using Cohen’s kappa statistic. A κ value of 0.50 indicated moderate agreement beyond chance between the two methods (p< 0.001).

Conclusion: This study showed that preoperative clinical and imaging-based axillary assessment showed high specificity but only moderate sensitivity when compared with final histopathology in upfront surgery cases.

Downloads

Download data is not yet available.

References

1. Pinheiro DJ, Elias S, Nazário AC. Axillary lymph nodes in breast cancer patients: sonographic evaluation. Radiol Bras 2014; 47(4): 240-244. https://doi.org/10.1590/0100-3984.2013.1689

2. Donker M, van Tienhoven G, Poncet C,. Sauvé N, Straver ME, van de Velde CJH, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (AMAROS): 10-year follow-up. J Clin Oncol 2023; 41(12): 2159–2168.

https://doi.org/10.1016/s1470-2045(14)70460-7

3. Limberg JN, Jones T, Thomas SM, Ntowe KW, Dalton JC, van den Bruele AB, et al. Omission of axillary lymph node dissection in patients with residual nodal disease after neoadjuvant chemotherapy. Ann Surg Oncol 2024; 31(13): 8813–8820.

https://doi.org/10.1245/s10434-024-16143-6

4. Tseng LJ, Matsuyama A, MacDonald-Dickinson V. Histology: the gold standard for diagnosis? Can Vet J 2023; 64(4): 389–390.

5. Goyal S, Jacob LA, Lokanatha D, Suresh Babu M, Lokesh K, Rudresha A, et al. Discordance in clinical versus pathological staging in breast cancer: are we undermining the significance of accurate preoperative staging in the present era? Breast Dis 2021; 41(1): 115–121. https://doi.org/10.3233/BD-201029

6. Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, et al. Effect of axillary dissection vs no axillary dissection on overall survival among women with invasive breast cancer and sentinel node metastasis. JAMA 2022; 327(8): 720–729. https://doi.org/10.1001/jama.2017.11470

7. Bartels SAL, Donker M, Poncet C, Meijnen P, van de Velde CJ, Mansel RE, et al. Axillary management in early breast cancer: long-term results of the AMAROS trial. Lancet Oncol 2020; 21(10): 1315–1324.

https://doi.org/10.1016/s1470-2045(14)70460-7

8. Sharaf B, Seif A, Alawneh F, Bani Hani H, Sh Abrahim M, Jehad S, et al. De-escalating breast and axillary surgery in breast cancer: evidence, controversies, and future directions. Front Oncol 2026; 16: 1717340.https://doi.org/10.3389/fonc.2026.17173403

9. Alvarez S, Añorbe E, Alcorta P, López F, Alonso I, Cortés J. Role of axillary ultrasound in the diagnosis of lymph node metastases in breast cancer. Eur Radiol 2021; 31(3): 1620–1629.

https://doi.org/10.2214/ajr.05.0936

10. Pilewskie M, Morrow M. Axillary nodal management following ultrasound staging in breast cancer. Ann Surg Oncol 2020; 27(6): 1890–1898. https://doi.org/10.1001/jamaoncol.2016.4163

11. Rezkallah EMN, Elsaify A, Tin SMM, Elsaify W. Diagnostic Accuracy of Ultrasonography in Axillary Staging in Breast Cancer Patients. J Med Ultrasound 2023; 31(4): 293-297.

https://doi.org/10.4103/jmu.jmu_99_22

12. Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet 2021; 397(10286): 1750–1769.

https://doi.org/10.1016/s0140-6736(20)32381-3

13. Farooq HF, Aslam S, Gul A, Masud S, Zaidi B, Subzwari SAHW. Diagnostic Accuracy of Axillary Ultrasonography for Differentiating Benign and Malignant Lymph Nodes in Breast Cancer Patients: Diagnostic Accuracy of Axillary Ultrasound for Lymph Nodes. Dev med life sci 2025; 2(3): 4-8.

https://doi.org/10.69750/dmls.02.03.099

14. Sultan N, Memon SA, Mooghal M, Wali S, Khan W, Tahseen H, et al. Ethnic predisposition, risk factors and breast cancer presentation; a 10-year data. Single centered prospective cohort study from Karachi. Ann Med Surg 2022; 82: 104612.

https://doi.org/10.1016/j.amsu.2022.104612

15. Morrow M, Van Zee KJ, Patil S, Mamtani A, Barrio AV. Axillary dissection and nodal radiation: evolving concepts in early breast cancer. N Engl J Med 2022; 386(11): 1047–1056.

https://doi.org/10.1056/NEJMra2108731

16. Damin AP, Zancan M, Melo MP, Biazus JV. Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer: guiding a more selective axillary approach. Breast Cancer Res Treat 2021; 186(2): 527-534.

https://doi.org/10.1007/s10549-020-06011-8

17. Senkus E, Cardoso MJ, Kaidar-Person O, Łacko A, Meattini I, Poortmans P. De-escalation of axillary irradiation for early breast cancer - Has the time come? Cancer Treat Rev 2021; 101: 102297.

https://doi.org/10.1016/j.ctrv.2021.102297

18. Brackstone M, Baldassarre FG, Perera FE, et al. Management of the axilla in early-stage breast cancer: ASCO guideline update. J Clin Oncol 2021; 39(27): 3056–3082.

https://doi.org/10.1200/JCO.21.00934